GIP and diabetes mellitus: It suffices to mention, for example, glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP), from which several drugs have already been derived and used widely in the treatment of diabetes and obesity, with additional candidates in the pipeline and potential for therapy of cardiovascular, renal, and cerebral diseases as well [2, 3, 4].